| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Posard Matthew L. is a Director at HALO, with reported holdings spanning 2 companies. Recent filings cover 4 purchases and 16 sales. Those positions are worth an estimated $6.0M at current prices.
Our model assigns Posard Matthew L. a below-average insider score of 46/100, based on 10 past trades. Over a 12-month horizon, 30.0% of those trades were profitable, with an average 12-month return of -9.3%.
Posard Matthew L.'s largest disclosed position is in HALO as Director, worth about $5.8M. The recent filings there lean toward selling, a net 104,107 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | HALO Halozyme Therapeutics, Inc. | Director | Sell | 5,230 | $108.54 | $567,660.74 | -8.9% | - | - | |
| Sep 16, 2026 | HALO Halozyme Therapeutics, Inc. | Director | Sell | 18,996 | $107.74 | $2,046,581.04 | -24.4% | - | - | |
| Aug 14, 2024 | HALO Halozyme Therapeutics, Inc. | Director | Sell | 29,881 | $56.53 | $1,689,293.70 | -30.0% | +3.8% | +14.2% | |
| Jun 12, 2024 | HALO Halozyme Therapeutics, Inc. | Director | Sell | 20,000 | $50.32 | $1,006,300.00 | -16.7% | +19.3% | +9.8% | |
| Dec 6, 2022 | HALO Halozyme Therapeutics, Inc. | Director | Sell | 30,000 | $56.89 | $1,706,550.00 | -22.2% | -19.3% | -29.1% | |
| Dec 1, 2021 | NAUT Nautilus Biotechnology, Inc. | Director | Buy | 50,000 | $4.51 | $225,505.00 | New | -12.1% | -59.1% |